XOLAIR 150 MG / 1 ML — DIN 02459795
OMALIZUMAB : 150 MG / 1 ML · NOVARTIS PHARMACEUTICALS CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is XOLAIR?
XOLAIR 150 MG / 1 ML contains OMALIZUMAB : 150 MG / 1 ML. It is listed in the Health Canada Drug Product Database under DIN 02459795, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 06-Jul-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XOLAIR used for?
Moderate to severe persistent allergic asthma (6+ years); Severe chronic rhinosinusitis with nasal polyps (adults); Chronic idiopathic urticaria (12+ years) symptomatic despite H1 antihistamines.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Omalizumab cost around the world?
Omalizumab is listed on 14 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 2 | 74 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 2 | 12 | CZK███.██ |
| Romania | max producer price | 5 | 10 | RON███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 9 | NOK███.██ |
| Greece | producer price (ex-factory) | 8 | 8 | EUR███.██ |
| Hungary | producer price (ex-factory) | 8 | 8 | HUF███.██ |
| Slovakia | categorised final price | 7 | 7 | EUR███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 6 | EUR███.██ |
| United Arab Emirates | public | 5 | 5 | AED███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 3 | BHD███.██ |
| Saudi Arabia | public | 2 | 3 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 2 | EUR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
152 pack listings across 55 brand entries and 12 price bases, refreshed 08 Sep 2026. Ranges span every Omalizumab pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Omalizumab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Omalizumab, across 9 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 7 | 6 | XOLAIR | Sourceable in Canada |
| CELLTRION INC. | 2 | 2 | OMLYCLO | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG / 1 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Pack configuration (monograph) | 150 mg single-use vial (lyophilized); Pre-filled syringes and pens in 75 mg/0.5 mL, 150 mg/1.0 mL, and 300 mg/2.0 mL strengths. |
| Storage | Reconstituted solution: 2-8°C for up to 8 hours or 25°C for 2 hours. (Note: Full storage for unopened product not in snippet, but stability for reconstituted is provided). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Omalizumab |
|---|---|
| ATC code | R03DX05 |
| AHFS class | 90:28.16.92 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02459795 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2459795 |
| Brand name | XOLAIR |
| Generic / active ingredient | OMALIZUMAB : 150 MG / 1 ML |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | R03DX05 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03DX |
| Current status | MARKETED |
| Status date | 06-Jul-2017 |
| Original market date | 2017-07-06 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
75 to 600 mg SC every 2 or 4 weeks. Dose based on serum total IgE level and body weight for asthma/nasal polyps. For CIU, 150 or 300 mg every 4 weeks regardless of IgE/weight.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to omalizumab or any component of the formulation, or previous severe hypersensitivity reaction to Xolair.
Warnings and precautions
Serious Warning: Anaphylaxis (life-threatening) can occur after any dose. Monitor patients in a healthcare setting. Risk of Churg-Strauss syndrome and malignant neoplasms.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 9 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMLYCLO | 150 MG / 1 ML | SOLUTION | CELLTRION INC. | MARKETED | 02553813 |
| OMLYCLO | 75 MG / 0.5 ML | SOLUTION | CELLTRION INC. | MARKETED | 02553805 |
| XOLAIR | 75 MG / 0.5 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02545136 |
| XOLAIR | 150 MG / 1 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02545144 |
| XOLAIR | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02545160 |
| XOLAIR | 150 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02260565 |
| XOLAIR | 75 MG / 0.5 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02459787 |
| XOLAIR | 300 MG / 2 ML | SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | APPROVED | 02545152 |
2 · Same class — other molecules in ATC R03DX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Omalizumab | OMLYCLO · XOLAIR | 9 | 8 | Yes |
| Mepolizumab | NUCALA | 4 | 3 | Yes |
| Benralizumab | FASENRA · FASENRA PEN | 2 | 2 | Yes |
| Tezepelumab | TEZSPIRE | 2 | 2 | Yes |
| Reslizumab | CINQAIR | 1 | 1 | Yes |
| Roflumilast | DAXAS | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03DC | Montelukast · Zafirlukast | 98 | 41 |
| R03DA | Aminophylline · Choline Theophyllinate · Diprophylline · Theophylline · Theophylline, Combinations Excl. Psycholeptics | 82 | 8 |
| R03DB | Theophylline And Adrenergics | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is XOLAIR called?
The same molecule, Omalizumab, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Omlyclo | Latin | Australia, Czechia, Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.